Disclosed are anti-TrkA antibodies with improved binding affinity to TrkA-IgG, a Nerve growth factor receptor. The disclosed antibodies are useful in treating Alzheimers disease, cancer, diabetes, leprosy, pancreatitis and neuropathic pain, along with various other disorders. Further disclosed is a pharmaceutical composition comprising said antibody and another pharmaceutically active agent. Also disclosed is a nucleic acid encoding said antibody, a vector comprising said nucleic acid, and a non-human transgenic mammal that expresses said antibody.
